Litcius/Paper detail

Comprehensive Review on Molnupiravir in COVID-19: A Novel Promising Antiviral to Combat the Pandemic

Sajad Khiali, Elnaz Khani, Samineh B Rouy, Taher Entezari‐Maleki

2022Future Microbiology20 citationsDOIOpen Access PDF

Abstract

Despite the progress in the management of COVID-19, effective oral antiviral agents are still lacking. In the present review, the potential beneficial effects of molnupiravir in the management of COVID-19 are discussed. A literature search in Google Scholar, Scopus, PubMed and clinicaltrials.gov for the relevant articles regarding the pharmacokinetics, pharmacodynamics and clinical trials of molnupiravir in the management of COVID-19 is conducted. Most of the preclinical studies and available clinical trials showed a favorable short-term safety profile of molnupiravir; however, given its possible genotoxic effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir in patients with COVID-19.

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Clinical trialPandemicPharmacodynamicsMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakIntensive care medicineSafety profilePharmacologyPharmacokineticsAdverse effectVirologyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchRespiratory viral infections researchViral gastroenteritis research and epidemiology
Comprehensive Review on Molnupiravir in COVID-19: A Novel Promising Antiviral to Combat the Pandemic | Litcius